DNB Related Funding Opportunities

Genetics, Epigenetics, and Developmental Neuroscience Branch (GEDN)

Program Announcements

  • PAR-21-244 – NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed)
  • PAR-21-208 – Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) 

Requests for Application

  • RFA-DA-23-012 – Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional) 
  • RFA-DA-22-040 High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

Notices of Special Interest (NOSI)

  • NOT-DA-23-004– Notices of Special Interest (NOSI): High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior
  • NOT-DA-21-020 Notice of Special Interest (NOSI): Evaluation of sex differences on HIV-associated comorbidities in the context of stimulant use
  • NOT-DA-20-039 – Notice of Special Interest (NOSI): Effects of Cannabis Use and Cannabinoids on the Developing Brain 
  • NOT-DA-20-030 – Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorders 
  • NOT-NS-20-024 – Notice of Special Interest: Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) – U.S. Entity (Admin Supp) 
  • NOT-DA-20-020 – Notice of Special Interest (NOSI): Going Global: Using Gene Network Analyses to Understand the Etiology of SUD 
  • NOT-DA-20-018 – Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related processes 

Chemistry and Pharmacology Branch (CP)

Program Announcements

  • PAR-22-209 – CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
  • PAR-22-032 – Drug Discovery for Nervous System Disorders (R21 Clinical Trials Not Allowed) 
  • PAR-22-031 – Drug Discovery for Nervous System Disorders (R01 Clinical Trials Not Allowed)
  • PAR-21-029 – Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed) 
  • PAR-21-028 – Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed) 

Requests for Application

  • RFA-NS-21-010 – HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) 

Notices of Special Interest (NOSI)

  • NOT-DA-23-002 – Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs 
  • NOT-DA-21-033 – Notice of Special Interest (NOSI): Basic Research on Fentanyl and Synthetic Fentanyl Analogs: Signaling, Neurobiology, and Pharmacology 
  • NOT-DA-21-028 – Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects 

Behavioral and Cognitive Neuroscience Branch (BCN)

Program Announcements

  • PAR-21-352 – Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trial Required) 
  • PAR-21-350 – Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed) 
  • PAR-21-349 – Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required) 
  • PAR-21-309 – Imaging – Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required) 
  • PAR-21-310 – Imaging – Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional)

Notices of Special Interest (NOSI)

  • NOT-DA-21-030 – Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience 
  • NOT-DA-21-012 - Notice of Special Interest (NOSI): Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence 
  • NOT-AT-21-002 – Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease 
  • NOT-DA-20-022 – Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience 
  • NOT-DA-20-017 – Notice of Special Interest (NOSI): Harnessing computational tools for sophisticated analyses of Substance Use Disorder-related behaviors 
  • NOT-DA-20-006 – Notice of Special Interest (NOSI): Mentored Career Development Award in Large-Scale Clinical Study Development and Analysis 
  • NOT-DA-20-005 – Notice of Special Interest (NOSI): Mechanistic Investigations of Psychosocial Factors Associated with Substance Use Disorders 
  • NOT-DA-21-003 - Notice of Special Interest (NOSI): Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder 

Notices

  • NOT-OD-22-084 – Notice of Intent to Publish the Reissuance of RFA-OD-20-010, Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 – Independent Clinical Trial Required) 
  • NOT-OD-22-083 – Notice of Intent to Publish the Reissuance of RFA-OD-20-009, Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 – Independent Clinical Trial Not Allowed) 
  • NOT-OD-22-082 - Notice of Intent to Publish the Reissuance of RFA-OD-20-011, Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 – Independent Clinical Trial Required) 
  • NOT-OD-22-081 – Notice of Intent to Publish the Reissuance of RFA-OD-20-008, Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 – Independent Clinical Trial Not Allowed) 

Integrative Neuroscience Branch

Program Announcements

  • PAR-20-249 – NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) 
  • PAS-21-270 – AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) 
  • PAR-21-320 – NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) 

Requests for Application

  • RFA-OD-22-015 – Galvanizing Health Equity Through Novel and Diverse Educational Resources (GENDER) Research Education R25 (R25 Clinical Trial Not Allowed)

Notices of Special Interest (NOSI)

  • NOT-DA-22-058 – Notices of Special Interest (NOSI): High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior 
  • NOT-DA-22-047 – Notice of Special Interest (NOSI): Mechanistic studies on the impact of substance use in sex and gender differences in HIV-associated neurocognitive disorders 
  • NOT-DA-21-030 – Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience 
  • NOT-DA-21-006 - Notice of Special Interest (NOSI): Leveraging transformative connectome resources in model organisms to elucidate the neurobiology of substance use disorders 
  • NOT-DA-21-014 - Notice of Special Interest (NOSI): Identification of Biomarkers of HIV Pathogenesis and Substance Use Disorder Comorbidity 
  • NOT-DA-21-001 – Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain 
  • NOT-DA-20-060 – Notice of Special Interest (NOSI): Role of Astrocytes and Astrocytic Networks in Drug Abuse 
  • NOT-DA-20-046 – Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders 
  • NOT-DA-20-022 – Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience 
  • NOT-DA-20-021 – Notice of Special Interest (NOSI): Sleep and Substance Use Disorders 

Notices

  • NOT-DA-22-070 – Notice of Intent to Publish a Funding Opportunity Announcement for Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) 
  • NOT-DA-22-055 – Notice of Change to section for PAR-21-320, “NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)” 

Office of the Director

Program Announcements 

  • PAR-21-320 – NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) 

Notices of Special Interest (NOSI)

  • NOT-MH-21-175 – Notice of Special Interest (NOSI) regarding the use of Human Connectome Data for Secondary Analysis 
  • NOT-AI-21-054 – Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV 
  • NOT-DA-21-030 – Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience 
  • NOT-DA-21-013 – Notice of Special Interest (NOSI): High-Priority Interest to Enhance Data Science Research Training in Addiction Research 
  • NOT-DA-21-004 – Notice of Special Interest (NOSI): Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction 
  • NOT-DA-23-006 – Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment 
  • NOT-DA-20-022 – Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience

Notices

  • NOT-DA-22-055 – Notice of Change to section for PAR-21-320, “NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)”